| Literature DB >> 33201310 |
Marly F J A van der Lubbe1, Akshayaa Vaidyanathan2,3, Vincent Van Rompaey4, Alida A Postma5,6, Tjasse D Bruintjes7,8, Dorien M Kimenai9, Philippe Lambin2, Marc van Hoof10, Raymond van de Berg10,6.
Abstract
BACKGROUND: Classifying and diagnosing peripheral vestibular disorders based on their symptoms is challenging due to possible symptom overlap or atypical clinical presentation. To improve the diagnostic trajectory, gadolinium-based contrast-enhanced magnetic resonance imaging of the inner ear is nowadays frequently used for the in vivo confirmation of endolymphatic hydrops in humans. However, hydrops is visualized in both healthy subjects and patients with vestibular disorders, which might make the clinical value of hydrops detection on MRI questionable.Entities:
Keywords: Disease; Distinctiveness; Endolymphatic hydrops; Magnetic resonance imaging; Menière’s; Symptoms; Vestibular disorders
Mesh:
Substances:
Year: 2020 PMID: 33201310 PMCID: PMC7718205 DOI: 10.1007/s00415-020-10278-8
Source DB: PubMed Journal: J Neurol ISSN: 0340-5354 Impact factor: 4.849
The estimated prevalences in unilateral and bilateral Menière's disease
| Feature | Descriptiona | Sample sizesb (n) | Agec (year) | Estimated prevalence (%) | Ranged | Reliabilitye | References |
|---|---|---|---|---|---|---|---|
| Headache | Headache N.O.S. | 55–119 | > 19 | 64.1 | 41.2–81 | 3 | [ |
| Tinnitus | Tinnitus N.O.S. | 55–501,306 | > 37 | 82.1 | 59–91.4 | 2 | [ |
| Dizziness** | Dizziness N.O.S. | – | – | 100 | – | 1 | - |
| Hearing loss | Any subjective difficulty with hearing | 55–1376 | > 37 | 76.4 | 55–93 | 2 | [ |
| Otalgia | Otalgia N.O.S. | 55 | – | 17 | – | 1 | [ |
| Aural fullness | Aural fullness N.O.S. | 37–726 | > 20 | 73.4 | 65–80.6 | 3 | [ |
| Migraine | Migrainous headaches | 37–119 | > 18 | 27.4 | 8.4–51 | 2 | [ |
| Vertigo | Vertigo N.O.S. | 37 | > 20 | 100 | – | 1 | [ |
| Falls | Falls without external factors | 501,306 | > 37 | 14.6 | 13.7–15.4 | 2 | [ |
| EH (histology) | Endolymphatic hydrops in any part of the labyrinth except for the apical turn | 28–165 | – | 99.4 | 98.8–100 | 3 | [ |
| EH (radiology) | Mild cochlear or vestibular hydrops | 18–396 | > 7 | 82.3 | 44.4–100 | 3 | [ |
| EH (radiology) | Mild cochlear or vestibular hydrops in the asymptomatic contralateral ear | 23–198 | > 7 | 27.6 | 8.6–65 | 3 | [ |
| EH* (radiology) | Mild cochlear or vestibular hydrops in “possible” MD | 7–122 | > 16 | 77.7 | 41.1–100 | 3 | [ |
Data were not available
N.O.S. Not otherwise specified
aSymptom and hydrops description. In case of heterogenous or missing descriptions, the feature was defined as N.O.S
bLower and upper limits of the combined sample sizes
Lower limit of the combined age samples
dRange of the combined prevalences
eThe reliability of the combined results defined by a 5-point scoring system: 5 = high reliability, 1 = low reliability
*Hydrops prevalences in patients with only one symptom like hearing loss or isolated vertigo spells (cochlear or vestibular MD)
**Dizziness was estimated to be 100% prevalent among patients with Menière’s disease since vertigo was 100% prevalent
The estimated prevalences in patients diagnosed with vestibular schwannoma
| Feature | Definitiona | Sample sizesb (n) | Agec (year) | Estimated prevalence (%) | Ranged | Reliabilitye | References |
|---|---|---|---|---|---|---|---|
| Headache | Headache N.O.S. | 122–541 | > 13 | 25.2 | 18–36 | 4 | [ |
| Tinnitus | Tinnitus N.O.S. | 122–541 | > 13 | 63.8 | 56–83 | 3 | [ |
| Dizziness | Dizziness N.O.S. | 126–206 | > 17 | 33.3 | 23–48 | 2 | [ |
| Hearing loss | Any subjective or objective hearing loss | 122–541 | > 13 | 91 | 85–97 | 3 | [ |
| Otalgia | Otalgia N.O.S. | 126 | > 17 | 12 | – | 1 | [ |
| Aural fullness | Ear pressure N.O.S. | 541 | Adults | 28 | – | 2 | [ |
| Migraine | Migraine (diagnostic criteria) | 122 | > 13 | 4.9 | – | 1 | [ |
| Vertigo | Vertigo N.O.S. | 122–206 | > 13 | 24.4 | 5,3–49 | 2 | [ |
| CPA tumor (radiology) | Requirement for diagnosis | – | – | 100 | – | 1 | – |
| EH (histology) | Distension of Reissner’s membrane in vestibule or cochlea | 11–12 | > 44 | 48.2 | 36.4–60 | 2 | [ |
| EH* (radiology) | Cochlear or vestibular hydrops | 13–183 | > 26 | 25.9 | 21–30.8 | 1 | [ |
Data were not available
N.O.S. Not otherwise specified
aSymptom and hydrops definition. In case of heterogenous or missing descriptions, the feature was defined as N.O.S
bLower and upper limits of the combined sample sizes
cLower limit of the combined age samples
dRange of the combined prevalences
e The reliability of the combined results defined by a 5-point scoring system: 5 = high reliability, 1 = low reliability
*EH was detected with non-contrast-enhanced MR imaging
The estimated prevalences in patients diagnosed with vestibular migraine
| Feature | Descriptiona | Sample sizesb (n) | Agec (year) | Estimated prevalence (%) | Ranged | Reliabilitye | References |
|---|---|---|---|---|---|---|---|
| Headache | Headache N.O.S. | 71–84 | - | 97.1 | 95.2–99 | 2 | [ |
| Tinnitus | Tinnitus N.O.S. | 16–252 | > 19 | 44.8 | 26–55 | 1 | [ |
| Hearing loss | Any subjective difficulty with hearing | 71–252 | > 19 | 32.5 | 14–89 | 2 | [ |
| Otalgia | Otalgia N.O.S. | 71 | – | 27 | – | 1 | [ |
| Aural fullness | Aural fullness N.O.S. | 16–252 | > 19 | 37.6 | 12–70 | 2 | [ |
| Migraine | Migrainous headaches | 16–84 | Adults | 80 | 56–100 | 2 | [ |
| Vertigo | Sensation of spinning, swaying or tilting | 252 | > 19 | 73 | – | 1 | [ |
| EH (radiology) | Mild cochlear or vestibular hydrops | 7–60 | > 26 | 28.1 | 0–85.7 | 1 | [ |
Data were not available
N.O.S. Not otherwise specified
aSymptom and hydrops definition. In case of heterogenous or missing descriptions, the feature was defined as N.O.S
bLower and upper limits of the combined sample sizes
cLower limit of the combined age samples
dRange of the combined prevalences
eThe reliability of the combined results defined by a 5-point scoring system: 5 = high reliability, 1 = low reliability
The estimated prevalences in the general population
| Feature | Descriptiona | Sample sizesb ( | Agec (years) | Estimated prevalence (%) | Ranged | Reliabilitye | References |
|---|---|---|---|---|---|---|---|
| Headache | Headache N.O.S. | > 200 | > 3 | 41.1 | 16–60.2 | 4 | [ |
| Tinnitus | Tinnitus N.O.S. | 4083–15,445 | > 14 | 18.6 | 17–20.3 | 4 | [ |
| Dizziness | Dizziness N.O.S. | 1003–3267 | > 18 | 18.5 | 16.7–24.2 | 5 | [ |
| Hearing loss | Any objective hearing loss > 25 dB | 3267–7490 | > 18 | 12.9 | 7.2–16.1 | 5 | [ |
| Otalgia | Otalgia not associated with infection or otitis | 411 | > 25 | 12.5 | – | 1 | [ |
| Aural fullness | Aural fullness not associated with infection | 411–866 | > 25 | 12.4 | 7–17.8 | 2 | [ |
| Migraine | Migraine (diagnostic criteria) | > 200 | > 3 | 10.5 | 10–11 | 4 | [ |
| Vertigo | Rotational, positional or recurrent vertigo | 1003–4869 | > 18 | 8.4 | 4.9–15.2 | 4 | [ |
| Falls | Falls without external factors | 2394–3267 | > 40 | 5.5 | 1.5–11.5 | 5 | [ |
| CPA tumor (radiology) | Cerebellopontine angle tumor on MRI | 2000 | > 45 | 0.2 | – | 1 | [ |
| EH (histology) | Distension of Reissner’s membrane in vestibule or cochlea | 560–703 | > 0 | 14.3 | 9–19.5 | 4 | [ |
Data were not available
N.O.S. Not otherwise specified
aSymptom and hydrops descriptions. In case of heterogeneous or missing descriptions, the feature was defined as N.O.S
Lower and upper limits of the combined sample sizes
Lower limit of the combined age samples
dRange of the combined prevalences
eThe reliability of the combined results defined by a 5-point scoring system: 5 = high reliability, 1 = low reliability
The estimated prevalences in the healthy references with no vestibular history
| Feature | Descriptiona | Sample sizesb ( | Agec (year) | Estimated prevalence (%) | Ranged | Reliabilitye | References |
|---|---|---|---|---|---|---|---|
| Headache* | Headache N.O.S. | – | – | 20.1 | – | 1 | [ |
| Tinnitus | Tinnitus N.O.S. | 78–501,306 | > 10 | 20.4 | 8.1–32.5 | 2 | [ |
| Hearing loss | Any subjective difficulty with hearing | 78–501,306 | > 37 | 26.2 | 25.4–27 | 3 | [ |
| Dizziness | Dizziness N.O.S. | 78–282 | > 10 | 17 | 16–18 | 3 | [ |
| Otalgia | Otalgia not associated with infection or otitis | 1387 | > 18 | 25.5 | – | 1 | [ |
| Aural fullness | Aural fullness not associated with infection | 78 | > 10 | 12 | – | 1 | [ |
| Migraine | Migraine (diagnostic criteria) | 501,306 | > 37 | 2.9 | – | 2 | [ |
| Vertigo | Rotational, positional or recurrent vertigo | 326–368 | > 11 | 4.9 | 3.5–7.3 | 3 | [ |
| Falls | Falls without external factors | 282–501,306 | > 37 | 3.8 | 1–6.6 | 4 | [ |
| CPA tumor (radiology) | Cerebellopontine angle tumor on MRI | 24,246–46,414 | > 20 | 0.05 | 0.02–0.07 | 4 | [ |
| EH (histology) | Distension of Reissner’s membrane in the cochlea | 24–118 | > 0 | 12.5 | 3.5–17 | 3 | [ |
| EH (radiology) | Mild cochlear or vestibular hydrops | 22–32 | > 20 | 31 | 0–100 | 3 | [ |
Data were not available
N.O.S. Not otherwise specified
aSymptom and hydrops definition. In case of heterogenous or missing descriptions, the feature was defined as N.O.S
bLower and upper limits of the combined sample sizes
Lower limit of the combined age samples
dRange of the combined prevalences
eThe reliability of the combined results defined by a 5-point scoring system: 5 = high reliability, 1 = low reliability
*Headache prevalence in the healthy population was estimated by subtracting the percentage of headaches associated with dizziness from the overall prevalence of headache in the general population
Fig. 1Graphical representation of feature distinctiveness in a four-dimensional (x,y,r,α) bubble chart. Estimated prevalences in patients diagnosed with MD and in healthy references were plotted on the x-axis and y-axis, respectively. This resulted in a low, moderate, or high level of distinctiveness. The overall feature prevalence in both health and disease were presented as bubble size (r). The reliability of the results were presented by transparency (α). Features plotted under the reference line were distinctive for MD. The absolute distance between EH (histology) and EH (radiology) represented the discrepancy in distinctiveness between the two techniques
Fig. 2Graphical representation of feature distinctiveness in a four-dimensional (x,y,r,α) bubble chart. Estimated prevalences in patients diagnosed with vestibular schwannoma and healthy references were plotted on the x-axis and y-axis, respectively. This resulted in a low, moderate, or high level of distinctiveness. The overall feature prevalence in both health and disease were presented as bubble size (r). The reliability of the results was presented by transparency (α). Features plotted under the reference line were distinctive for vestibular schwannoma. The absolute distance between EH (histology) and EH (radiology) represented the discrepancy in distinctiveness between the two techniques
Fig. 3Graphical representation of feature distinctiveness in a four-dimensional (x, y, r, α) bubble chart. Estimated prevalences in patients diagnosed with vestibular migraine and healthy references were plotted on the x-axis and y-axis, respectively. This resulted in a low, moderate, or high level of distinctiveness. The overall feature prevalence in both health and disease were presented as bubble size (r). The reliability of the results were presented by transparency (α). Features plotted under the reference line were distinctive for vestibular migraine
An overview of test performance of hydrops imaging in the diagnosis of Menière’s disease
| Semi-quantitative grading method [ | Features beyond hydrops | ||||
|---|---|---|---|---|---|
| Author, year, reference | Author, year, reference | ||||
| Conte, 2019 [ | MD ( | Conte, 2019 [ | MD ( | ||
| Vestibular EH | SE: 74 (53–88) | Cochlear EH | SE: 74 (53–88) | Marker: | SE: 81 (61–93) |
| “Mild” | SP: 83 (62–95) | “Mild” | SP: 96 (77–100) | “VESCO” | SP: 96 (77–100) |
| PPV: 83(62–95) | PPV: 95 (74–100) | PPV: 96 (76–100) | |||
| NPV: 74 (53–88) | NPV: 77 (57–89) | NPV: 82 (62–93) | |||
| Yoshida, 2018 [ | MD ( | Bernaerts, 2019 [ | MD ( | ||
| Vestibular EH | SE: 94 | Cochlear EH | SE: 87 | Marker: | SE: 85 |
| “Mild” | SP: 93 | “Mild” | SP: 62 | addition of “Cochlear PE” | SP: 92 |
| PPV: 94 | PPV: 74 | ||||
| NPV: 93 | NPV:79 | ||||
| Vestibular EH | SE: 77 | Cochlear EH | SE: 71 | Attyé, 2017 [ | MD ( |
| “Significant” | SP:100 | “Significant” | SP: 91 | Marker | SE: 50 |
| PPV: 100 | PPV: 90 | “SURI” | SP:100 | ||
| NPV: 78 | NPV: 72 | ||||
| Attyé, 2017 [ | MD ( | ||||
| Vestibular EH | SE: 77 | Cochlear EH | SE: 60 | ||
| “Mild” | SP: 10 | “Mild” | SP: 33 | ||
| Vestibular EH | SE: 47 | Cochlear EH | SE: 37 | ||
| “Significant” | SP: 70 | “Significant” | SP: 87 | ||
SE sensitivity, SP specificity, PPV positive predictive value, NPV negative predictive value, VESCO vestibular endolymphatic space contacting the oval window, PE perilymphatic enhancement, SURI Saccule to utricle ratio inversion